Clearside Biomedical, Inc.
Clearside Biomedical is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). They develop and commercialize innovative ophthalmic treatments using their proprietary SCS Microinjector®, with a focus on targeted, non-surgical, office-based procedures. Their first FDA-approved product, XIPERE®, is used for treating macular edema associated with uveitis and is delivered via the suprachoroidal space. The company has a broad pipeline of small molecule and gene therapy candidates, and collaborates with various partners to expand the application of their platform. They are committed to improving patient outcomes and expanding access to ocular therapies.
Industries
Nr. of Employees
small (1-50)
Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200, Alpharetta, GA 30005
Patents
Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US-12127975-B2
View Details
Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US-12127975-B2
View DetailsProducts
FDA-approved therapeutic administered via suprachoroidal route
A corticosteroid suspension approved for treatment of macular edema associated with uveitis administered via suprachoroidal injection using a microinjector-based delivery method.
Phase 3-ready tyrosine kinase inhibitor suspension for wet AMD
A potent pan-VEGF tyrosine kinase inhibitor formulated as an injectable suspension intended for suprachoroidal administration to achieve targeted delivery and extended durability in neovascular AMD.
FDA-approved therapeutic administered via suprachoroidal route
A corticosteroid suspension approved for treatment of macular edema associated with uveitis administered via suprachoroidal injection using a microinjector-based delivery method.
Phase 3-ready tyrosine kinase inhibitor suspension for wet AMD
A potent pan-VEGF tyrosine kinase inhibitor formulated as an injectable suspension intended for suprachoroidal administration to achieve targeted delivery and extended durability in neovascular AMD.
Services
Selective licensing of suprachoroidal delivery technology to partners for clinical development and commercialization of ophthalmic therapeutics.
Formulation development and non-clinical study execution to support IND submissions for suprachoroidally administered product candidates.
Design and execution of clinical studies assessing safety, tolerability and efficacy of therapeutics administered to the suprachoroidal space across multiple retinal indications.
Selective licensing of suprachoroidal delivery technology to partners for clinical development and commercialization of ophthalmic therapeutics.
Formulation development and non-clinical study execution to support IND submissions for suprachoroidally administered product candidates.
Design and execution of clinical studies assessing safety, tolerability and efficacy of therapeutics administered to the suprachoroidal space across multiple retinal indications.
Expertise Areas
- Suprachoroidal drug delivery
- Ocular gene therapy delivery (viral and non-viral)
- Clinical trial management for retinal therapies
- Formulation development for long-acting ocular suspensions
Key Technologies
- Microneedle-based suprachoroidal injection
- Small-molecule injectable suspension formulations
- Viral (AAV) and non-viral DNA nanoparticle delivery
- Optical coherence tomography (OCT) imaging